Burning Rock Biotech Limited American Depositary Shares
BNR
Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$12.07 – $13.17
Volume28,086
Market cap$134M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for BNR.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for BNR.
Recent news
Company coverage with links to the original publishers.
Burning Rock Biotech Limited (NASDAQ: BNR) announced its annual general meeting scheduled for December 22, 2026, in Shanghai. The AGM will address three ordinary resolutions: ratification of Ernst & Young Hua Ming LLP as auditor, re-election of directors Zhihong Zhang and Wendy Hayes, and authorization for directors to implement these resolutions. The board of directors recommends shareholder approval of all proposals.
Wuhan Ammunition Life-tech Co. Ltd., a Chinese cancer screening company, is making a second attempt to list on the Hong Kong Stock Exchange amid a cooling biotech market. Despite doubling revenues to 15.42 million yuan in 2025, the company's net losses widened 26.8% and it faces a challenging valuation of 147x price-to-sales ratio. The sector has faced significant headwinds, with peers like New Horizon Health suspended for misconduct and Burning Rock Biotech facing delisting warnings.
Burning Rock Biotech Limited (NASDAQ: BNR) announced that all shareholder resolutions at its 2025 annual general meeting held on December 22, 2025 were approved. The resolutions included ratifying Ernst & Young Hua Ming LLP as auditor, re-electing directors Feng Deng and Licen Lisa Xu, and authorizing directors to implement the resolutions.
Burning Rock Biotech reported Q3 2025 financial results with total revenues of RMB 131.6 million, a slight 2.3% increase from the same period in 2024. The company saw decreased revenues in in-hospital and central laboratory channels but significant growth in pharma research and development services. Net loss was RMB 16.8 million, an improvement from RMB 35.7 million in the previous year.
Burning Rock and Riken Genesis received approval in Japan for a companion diagnostic system to guide treatment decisions for hormone-receptor-positive breast cancer patients using capivasertib.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.